Study of Effectiveness of Mexyn-A

Evangelical Synod Medical Centre279 enrolled

Overview

Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

The primary clinical endpoint was to establish MEXYN-A efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. The secondary endpoint was to measure the itch free period as a result of the new intervention.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

279

Conditions

Pruritus

Interventions

Mexyn-ADEVICE

Atomised topical self-chilled pressurised spray

Eligibility

Sex: ALLMin age: 5 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites. * Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered. Exclusion Criteria: * Patients who have taken any anti-pruritic drug during the month prior to participation. * Patients who have taken drugs for any reason for 2 days prior to participating in the study.

Locations (1)

Evangelical Synod Medical Centre

Cairo, Cairo Governorate, Egypt

Outcomes

Primary Outcomes

Treating Pruritus

Time frame: three days

Secondary Outcomes

measuring itch-free period after applying the new treatment, effect on sleep disturbance

Time frame: three days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.